GlassScriptPhysician profile
Minerva Santo Tomas
NPI 1699730978
$970.45
in general payments reported to CMS, 2019-2025
13 companies · $72.13 in 2025
The $72.13 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $55.99 · 2021: $23.58 · 2025: $72.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $221.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $192.55 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $92.82 | 2019 | |
| Merck Sharp & Dohme LLC | $91.27 | 2019 | |
| Novo Nordisk INC | $90.17 | 2019 | |
| Boston Scientific Corporation | $72.13 | 2025 | General - Therapies |
| Novartis Pharmaceuticals Corporation | $52.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $40.54 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $40.11 | 2019 | |
| Amgen INC. | $23.43 | 2019 | |
| Amryt Pharma Holdings LTD | $20.33 | 2020 | |
| Allergan, INC. | $19.17 | 2019 | |
| Glaxosmithkline, LLC. | $14.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minerva Santo Tomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.